CN105884777B - One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application - Google Patents
One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application Download PDFInfo
- Publication number
- CN105884777B CN105884777B CN201510315178.XA CN201510315178A CN105884777B CN 105884777 B CN105884777 B CN 105884777B CN 201510315178 A CN201510315178 A CN 201510315178A CN 105884777 B CN105884777 B CN 105884777B
- Authority
- CN
- China
- Prior art keywords
- egfr
- substituted amino
- compound
- kinases
- officinal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the 6 substituted amino purine compounds with the following chemical structure and its officinal salt,Wherein:R isOrR1 is hydrogen, fluorine, chlorine, bromine, methoxyl group or hydroxyl.The present invention provides 6 new substituted amino purine compounds and its officinal salt, and the suppression to EGFR kinases has selectivity, can effectively suppress EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)Activity, but to EGFRWTKinases does not have inhibition, so can both suppress the cell propagation of the overexpression of EGFR mutant or abnormal activation, so as to efficiently treat tumour, can avoid again because suppressing to normal structure EGFR in human bodyWTThe phosphorylation of kinases and the activation of associated signal paths, so as to bring larger toxic side effect, the drug responses such as fash, vomiting occur, improve therapeutic effect, reduce side reaction.
Description
Technical field
The invention belongs to technical field of medical chemistry, more particularly to one kind to act on selective depression EGFR sensitizing mutations and swash
Enzyme EGFRL858R, EGFR(d746-750)Active 6- substituted amino purines class compound and its application.
Background technology
Increasing with the life stress of people, living environment worse and worse, also get over compared to past by the incidence of disease of cancer
Come higher, therefore, the method for the treatment of of cancer and the effect for the treatment of are increasingly by the care and concern of medical personal.It is near several
Year, antineoplastic there has also been new progress, study more popular new antitumoral so far with the development of science and technology
Medicine has:Novel cell cytotoxic drug, endocrine therapeutic agents, genomic medicine, immunotherapy medicaments and molecular targeted antineoplastic
Thing.Wherein, the receptor tyrosine kinase inhibitors in molecular targeted antineoplastic and angiogenesis pathway inhibitor have good
Good prospect.
EGF-R ELISA (EGFR) is a kind of phosphorylating protein, is arranged by specific tyrosine residue sequence
The protein of row.EGF-R ELISA (EGFR) belongs to one of ErbB family members, and it is common with HER2, HER3 and HER4
Form ErbB extended familys.Research shows high expression or the unconventionality expression that EGFR in many entity tumors be present.EGFR and tumour
The propagation of cell, angiogenesis, tumor invasion, transfer and the suppression of Apoptosis are relevant.Its mechanism has:EGFR height
Expression causes the enhancing of downstream signal transduction;The increase of mutant egf R acceptors or ligand expression causes EGFR continuous activation;
The effect enhancing of autocrine loop;The destruction of receptor down-regulated mechanism;Activation of abnormal signal conduction path etc..EGFR overexpression exists
Played an important role in the evolution of malignant tumour, in the tissue such as spongiocyte, kidney, lung cancer, prostate cancer, cancer of pancreas, breast cancer
There is EGFR overexpression.Research to spongiocytoma finds that EGFR high expression is mainly relevant with its gene magnification.But have
When EGFR expressions dysregulation exist in translation and translation after.High expression of the EGFR in tumour is also possible to and activated
Degraded is reduced relevant afterwards, and some researchs point out that c-Src can raise EGFR water by suppressing acceptor ubiquitination and endocytosis
It is flat.With the presence of mutant egf R in many tumours, it has now been found that many kinds of EGFR saltant types.Mutant egf R effect may
Including:Cell continuous activation with part independent form acceptor;Caused due to EGFR some domains missing under acceptor
The destruction of tune mechanism, the activation of abnormal signal conduction path, suppression of Apoptosis etc..The generation of mutant is due to EGFR bases
Missing, mutation and the rearrangement of cause.
At present, the structure-activity relationship of EGFR inhibitor and uncertain, the compound of some structural difference very littles, it is directed to EGFR
The effect of suppression but differs greatly.The present inventor passes through painstaking efforts, and synthesize has choosing unexpectedly to EGFR mutant
The compound of selecting property inhibitory action, so as to the treatment for tumour, reduce the side reaction of inhibitor.
The content of the invention
The problem of an object of the present invention is low to solve EGFR inhibitor action effect, and side reaction is big, there is provided a kind of
Act on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746-750)6- substituted amino purine class compounds and its application.
The invention provides the 6- substituted amino purines compound with the following chemical structure and its officinal salt,
Wherein:
R is
R1 is hydrogen, fluorine, chlorine, bromine, methoxyl group or hydroxyl.
Further, the compound is selected from 6- (the chloro- pyrroles -2- methylaminos of 5-) purine or the 6- (chloro- pyrimidine -4- first of 6-
Amido) purine.
The present invention also provides a kind of above-mentioned 6- substituted amino purines compound and its officinal salt is preparing antineoplastic
In application.
The present invention provides a kind of above-mentioned 6- substituted amino purines compound and its officinal salt and dashed forward in preparation suppression EGFR again
Application in the cell proliferation of variant overexpression or abnormal activation.
The present invention provides a kind of medicine, drug regimen or reagent again, including above-mentioned 6- substituted amino purines compound and
Its officinal salt.
Further, the medicine, drug regimen or reagent are used to suppress the overexpression of EGFR mutant or abnormal activation
Cell propagation.
Further, the EGFR mutant is the EGFR kinases that mutation is produced in L858R or (d746-750) site.
Further, the medicine, drug regimen or reagent are used to treat or prevent tumour.
Further, the tumour is EGFR dependent tumors.
Further, the tumour includes lung cancer, intestinal cancer, oophoroma, kidney, carcinoma of urinary bladder, cavity cancer, stomach cancer or mammary gland
Cancer.
The beneficial effects of the present invention are:The present invention provides new 6- substituted amino purines compound and its officinal salt,
Suppression to EGFR kinases has selectivity, can effectively suppress EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746-750)'s
Activity, but to EGFRWTKinases do not have inhibition, so can both suppress the overexpression of EGFR mutant or abnormal activation
Cell is bred, and so as to efficiently treat tumour, can be avoided again because suppressing to normal structure EGFR in human bodyWTThe phosphoric acid of kinases
Change the activation with associated signal paths, so as to bring larger toxic side effect, the drug responses such as fash, vomiting occur.
Brief description of the drawings
Fig. 1 show the synthetic route of 6- of the present invention (the chloro- pyrroles -2- methylaminos of 5-) purine.
Fig. 2 show the synthetic route of 6- of the present invention (the chloro- pyrimidine -4- methylaminos of 6-) purine.
Embodiment
The specific embodiment of the invention is described in detail below in conjunction with specific accompanying drawing.It should be noted that in following embodiments
The combination of the technical characteristic or technical characteristic of description is not construed as isolated, and they can be mutually combined so as to reach
To superior technique effect.
The synthesis of the compound 6- of embodiment 1 (the chloro- pyrroles -2- methylaminos of 5-) purine (A1)
The synthetic route of 1 compound
Specific synthetic route is as shown in Figure 1.
It is 2-in-1 into step
The preparation of 2.16- (the chloro- pyrroles -2- methylaminos of 5-) purine (A1)
5ml n-butanol is measured, weighs 80mg 6-chloropurine and 100mg (the chloro- 1H- pyrroles -2- bases of 5-) methylamine,
It is put into 25ml round-bottomed flask, and the triethylamine for adding 50 μ l adds stirrer as catalyst.In 110 DEG C of oil bath heatings
Flow back 5h, cooling, treats that white solid separates out, and decompression filters, and is washed twice with n-butanol, dries, obtains the 6- (chloro- pyrroles -2- of 5-
Methylamino) purine (A1).
The physical features of 2.26- (the chloro- pyrroles -2- methylaminos of 5-) purine (A1)
1H-NMR(DMSO-d6)δ(ppm):12.987 (s, 1H, 7'or 9'-Purine-H), 8.220 (s, 1H ,-NH),
8.140-8.15 (m, 2H, 2', 8'-Purine-H), 7.858 (s, 1H, 1'-Pyrrole-H), 6.432-6.446 (m, 1H,
4'-Pyrrole-H), 6.252-6.283 (m, 1H, 3'-Pyrrole-H), 4.760 (s, 2H ,-CH2)。ESI-MS:249.1[M
+H]+。
The synthesis of the compound 6- of embodiment 2 (the chloro- pyrimidine -4- methylaminos of 6-) purine (A2)
The synthetic route of 1 compound
Specific synthetic route is as shown in Figure 2.
It is 2-in-1 into step
The preparation of 2.16- (the chloro- pyrimidine -4- methylaminos of 6-) purine (A2)
5ml n-butanol is measured, 80mg 6-chloropurine and 120mg (6- chlorine pyrimidine-4-yl) methylamine is weighed, is put into
In 25ml round-bottomed flask, and the triethylamine for adding 50 μ l adds stirrer as catalyst.Flowed back in 110 DEG C of oil bath heatings
5h, cooling, treat that white solid separates out, decompression filters, and is washed twice with n-butanol, dries, obtains the 6- (chloro- pyrimidine -4- methylamines of 6-
Base) purine (A2).
The physical features of 2.26- (the chloro- pyrimidine -4- methylaminos of 6-) purine (A2)
1H-NMR(DMSO-d6)δ(ppm):13.276 (s, 1H, 7'or 9'-Purine-H), 9.432 (s, 1H, 2'-
Pyrimidine-H), 8.720 (s, 1H ,-NH-), 8.125-8.243 (m, 2H, 2', 8'-Purine-H), 7.673 (s, 1H,
5'-Pyrimidine-H), 4.980 (s, 2H ,-CH2)。ESI-MS:262.6[M+H]+。
The Compound ira vitro EGFR inhibitory activity of embodiment 3 is tested
EGFR kinases external activity screens:The method that experiment uses is Caliper Mobility Shift Assay, should
Experiment is the detection platform using the mobility detection technique of microfluidic chip technology as core.Specifically experimental procedure is:Configuration
1.25x kinase reactions buffer solution (62.5mmol/L HEPES, pH7.5;0.001875%Brij-35;12.5mmol/L
MgCl2;2.5mmol/L DTT) and kinase reaction terminate liquid (100mmol/L HEPES, pH7.5;0.015%Brij-35;
0.2%Coating Reagent#3);(DMSO dissolves, and is diluted with water 10 times) adds in 5 μ l 5x concentration compound solutions
10 μ l 2.5x EGFR kinase solutions (in 1.25x kinase reaction buffer solutions plus kinases), are added after reacting at room temperature 10min
10 μ l 2.5x substrates peptide solution (in 1.25x kinase reaction buffer solutions plus FAM marks peptide and ATP), reacts special at 28 DEG C
25 μ l kinase reaction terminate liquids are added after the fixed time.The gather data on Caliper, to the inhibiting rate of kinase activity=
(max-conversion)/(max-min) ×100。
Compound A1 and compound A2 are determined to FGFR1, KDR, wild type under 5 μm of ol/L concentration by the above method
EGFR kinases, EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746-750)And EGFR mutant drug-resistant kinases EGFRT790MDeng kinases
Inhibitory activity, only the inhibition of EGFR mutant strains, inhibiting rate see the table below with characterizing inhibitor.
Compound A1 and compound A2 is under 5 μm of ol/L concentration to EGFRWT、EGFRL858R、EGFR(d746-750)It is and various
The inhibiting rate of kinases
By the above method respectively in 10000,3333,1111,370,123,41,14,5,2,1 (units:Nmol/L) etc.
Compound A1 and compound A2 is determined under 10 concentration to Wild type EGFR kinases, EGFR sensitizing mutation kinases EGFRL858R,
EGFR(d746-750)Inhibitory activity, IC50 results see the table below.
Compound A1 and compound A2 are to EGFRWT、EGFRL858RAnd EGFR(d746-750)IC50Value
Kinase assay shows:Compound A1 and compound A2 has very high selectivity to the EGFR kinases of mutation, especially
It is to EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746-750)With good inhibiting effect, reach nmol/L level,
But to FGFR1, the EGFR of KDR and wild type does not have inhibitory action.
The new 6- substituted amino purines compound and its officinal salt of the present invention, the suppression to EGFR kinases have selection
Property, it can effectively suppress EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746-750)Activity, but to EGFRWTKinases does not have
Inhibition, the cell propagation of the overexpression of EGFR mutant or abnormal activation so can be both suppressed, so as to efficiently treat
Tumour, it can avoid again because suppressing to normal structure EGFR in human bodyWTThe phosphorylation of kinases and the activation of associated signal paths,
So as to bring larger toxic side effect, the drug responses such as fash, vomiting occur, improve therapeutic effect, reduce side reaction.
Although having been presented for some embodiments of the present invention herein, it will be appreciated by those of skill in the art that
Without departing from the spirit of the invention, the embodiments herein can be changed.Above-described embodiment be it is exemplary, no
Restriction that should be using the embodiments herein as interest field of the present invention.
Claims (7)
- A kind of 1. application of 6- substituted amino purines compound and its officinal salt in antineoplastic is prepared;Its feature exists In the structure of described 6- substituted amino purine compounds is as follows:Wherein:R isR1It is hydrogen, fluorine, chlorine, bromine, methoxyl group or hydroxyl.
- 2. 6- substituted amino purines compound as claimed in claim 1 and its officinal salt answering in antineoplastic is prepared With, it is characterised in that the compound is selected from 6- (the chloro- pyrroles -2- methylaminos of 5-) purine or the 6- (chloro- pyrimidine -4- methylamines of 6- Base) purine.
- 3. 6- substituted amino purines compound and its officinal salt as described in any one of claim 1 or 2 prepare it is antitumor Application in medicine, it is characterised in that described antineoplastic is to suppress the overexpression of EGFR mutant or abnormal activation Cell proliferation.
- 4. 6- substituted amino purines compound as claimed in claim 3 and its officinal salt answering in antineoplastic is prepared With, it is characterised in that the EGFR mutant is in EGFRL858ROr EGFR(d746-750)Site produces the EGFR kinases of mutation.
- 5. 6- substituted amino purines compound as claimed in claim 3 and its officinal salt answering in antineoplastic is prepared With, it is characterised in that the antineoplastic is used to treat or prevent tumour.
- 6. 6- substituted amino purines compound as claimed in claim 5 and its officinal salt answering in antineoplastic is prepared With, it is characterised in that the tumour is EGFR dependent tumors.
- 7. 6- substituted amino purines compound as claimed in claim 6 and its officinal salt answering in antineoplastic is prepared With, it is characterised in that the tumour includes lung cancer, intestinal cancer, oophoroma, kidney, carcinoma of urinary bladder, cavity cancer, stomach cancer or breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510315178.XA CN105884777B (en) | 2015-06-09 | 2015-06-09 | One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510315178.XA CN105884777B (en) | 2015-06-09 | 2015-06-09 | One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105884777A CN105884777A (en) | 2016-08-24 |
CN105884777B true CN105884777B (en) | 2017-11-10 |
Family
ID=57002085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510315178.XA Active CN105884777B (en) | 2015-06-09 | 2015-06-09 | One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105884777B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106831730B (en) * | 2017-01-11 | 2019-11-26 | 温州医科大学 | A kind of substituted diaminopyrimidines and its preparing the purposes in anti-malignant tumor medicine |
CN113582995B (en) * | 2021-08-17 | 2022-08-16 | 西安交通大学 | 9-9H-purine compound containing acrylamide amino fragment at 9-position, and salt and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022805A2 (en) * | 2001-09-11 | 2003-03-20 | Albany Molecular Research, Inc. | Heterocycle substituted purines as antiproliferative agents |
WO2011113802A3 (en) * | 2010-03-17 | 2012-08-02 | F. Hoffmann-La Roche Ag | Imidazopyridine and purine compounds, compositions and methods of use |
WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
-
2015
- 2015-06-09 CN CN201510315178.XA patent/CN105884777B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022805A2 (en) * | 2001-09-11 | 2003-03-20 | Albany Molecular Research, Inc. | Heterocycle substituted purines as antiproliferative agents |
WO2011113802A3 (en) * | 2010-03-17 | 2012-08-02 | F. Hoffmann-La Roche Ag | Imidazopyridine and purine compounds, compositions and methods of use |
WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
Non-Patent Citations (1)
Title |
---|
"Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking";Ji-Xia Ren et al.;《Journal of Chemical Information and Modeling》;20110527;第51卷(第6期);第1364-1375页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105884777A (en) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohamed et al. | Medicinal attributes of pyridine scaffold as anticancer targeting agents | |
Battistutta et al. | Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole | |
JP5336606B2 (en) | Antitumor effect enhancer | |
Sarno et al. | ATP site-directed inhibitors of protein kinase CK2: an update | |
Ionescu et al. | DYRK1A kinase inhibitors with emphasis on cancer | |
Janes et al. | EphA3 biology and cancer | |
ES2856848T3 (en) | New 3,5-disubstituted-3H-imidazo [4,5-B] biridine and 3,5-disubstituida-3H- [1,2,3] triazolo [4,5-B] pyridine compounds as protein kinase modulators C-MET | |
EP3008053A1 (en) | Phosphatidylinositol 3-kinase inhibitors | |
EA025281B1 (en) | 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-b]PYRIDINE AND 3,5-DISUBSTITUED-3H-[1,2,3]TRIAZOLO[4,5-b]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | |
CN104918932B (en) | The amine derivative of N (base of pyridine 2) pyrimidine 4 of the imine group containing sulphur | |
CN105001168A (en) | Tri-alkoxy-substituted benzo quinazoline type tyrosine kinase inhibitor and application thereof | |
CN105884777B (en) | One kind acts on EGFR sensitizing mutation kinases EGFRL858R, EGFR(d746‑750)6 substituted amino purine class compounds and its application | |
EP2611795A1 (en) | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | |
CN105777716B (en) | A kind of EGFR inhibitor for targeted therapy of cancer and preparation method and application | |
CN102264699A (en) | Novel benzylidene-indolinone and their medical and diagnostic uses | |
CN103936742B (en) | Novel PI3K inhibitor containing purine radicals, preparation method and applications thereof | |
CN106146515A (en) | The preparation of Azaindole kinase inhibitors and application | |
Yuan et al. | Discovery, Optimization, and Structure–Activity Relationship Study of Novel and Potent RSK4 Inhibitors as Promising Agents for the Treatment of Esophageal Squamous Cell Carcinoma | |
US20090291961A1 (en) | Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer | |
CN105585557B (en) | EGFR inhibitor for targeted therapy of cancer and preparation method and application | |
CN104402861A (en) | Benzene sulfonamide derivatives, preparation method, and treatment application | |
CN105566329B (en) | A kind of pyrazoles [5,6-d] miazines EGFR inhibitor and its anti-tumor activity | |
CN101443021A (en) | Prevention and treatment of cancer and other diseases | |
Farag et al. | Medicinal attributes of thienopyrimidine scaffolds incorporating the aryl urea motif as potential anticancer candidates via VEGFR inhibition | |
Franco et al. | Bioactive Amino-Quinazolines: Synthesis and Therapeutic Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |